Skip to main content

Palboxen 125 mg (Palbociclib)

What is Palboxen 125 mg?

Palboxen 125 mg is identified as a palbociclib-containing product in the supplied product information for this website. Palbociclib is an oral targeted anticancer medicine classified as a cyclin-dependent kinase 4 and 6 inhibitor.

It is used in selected treatment combinations for advanced or metastatic breast cancer. Its principal established treatment role includes hormone receptor-positive and HER2-negative breast cancer, where it is combined with appropriate endocrine therapy.

Palbociclib is designed to interfere with cell-cycle proteins that help regulate cell division. By inhibiting CDK4 and CDK6, it can prevent susceptible cancer cells from progressing normally through the cell cycle.

The supplied product brief identifies Palboxen as a 125 mg product associated with Everest. This company attribution is based on the supplied product information and should be checked against the product’s packaging and official manufacturer documentation before being presented as independently verified.

What is Palbociclib?

Palbociclib is a targeted anticancer medicine that acts on two enzymes called cyclin-dependent kinase 4 and cyclin-dependent kinase 6.

These enzymes help regulate the cell cycle, the sequence of events through which a cell grows, copies its DNA and divides. In some breast cancer cells, the signaling pathways involving CDK4 and CDK6 are overactive and contribute to uncontrolled cell growth.

Palbociclib blocks CDK4 and CDK6 activity. This can prevent the phosphorylation of the retinoblastoma protein and interrupt progression from the G1 phase to the S phase of the cell cycle.

As a result, susceptible cancer cells may stop progressing through the cell cycle. This effect is known as cell-cycle arrest.

Palbociclib is not a hormone therapy itself. It is commonly combined with endocrine treatment because the two treatment approaches act on different but related pathways involved in hormone receptor-positive breast cancer.

Product Information

Product characteristicInformation
Product namePalboxen
Active ingredientPalbociclib
Stated strength125 mg
Therapeutic categoryAntineoplastic medicine
Pharmacological classCDK4/6 inhibitor
Main treatment areaSelected advanced or metastatic breast cancer
Principal receptor profileHR-positive, HER2-negative
Company stated in supplied briefEverest
Dosage formRequires confirmation from packaging
Administration routeOral for palbociclib products; confirm product documentation
Product authorizationMust be verified in the relevant country

What Does 125 mg Mean?

The number 125 mg describes the stated amount of active ingredient in the product strength. It is also a recognized starting dose in commonly used palbociclib treatment regimens.

However, the availability of a 125 mg strength does not mean every patient should receive 125 mg. A patient’s dose may need to be reduced because of adverse reactions, blood-count changes, liver-related findings, drug interactions or other clinical considerations.

Reference palbociclib labeling commonly describes dose levels of 125 mg, 100 mg and 75 mg. A healthcare professional determines whether a dose adjustment is necessary.

Patients should never divide, modify or combine doses to create a different strength unless the specific product instructions and treating specialist explicitly allow it.

What Type of Breast Cancer Is Palbociclib Used For?

Palbociclib has an established role in specified breast cancer treatment settings, particularly HR-positive, HER2-negative advanced or metastatic disease.

Hormone receptor-positive breast cancer: These cancer cells have receptors for hormones such as estrogen and/or progesterone. Hormone signaling may contribute to their growth.

HER2-negative breast cancer: These cancer cells do not meet the criteria for HER2-positive disease. HER2 status is determined through appropriate laboratory testing.

Advanced or metastatic breast cancer: Advanced disease may involve extensive local disease or cancer that has spread to other parts of the body. Metastatic breast cancer means that cancer has spread beyond the original breast site.

Palbociclib is not suitable for every patient with these diagnoses. The oncologist considers previous treatment, menopausal status, disease characteristics, overall health and the applicable treatment authorization before selecting a regimen.

Why Is Palbociclib Combined With Endocrine Therapy?

Hormone receptor-positive breast cancer can use estrogen signaling to support cancer-cell growth. Endocrine therapies aim to reduce estrogen production or block estrogen’s effects.

Palbociclib acts through a different pathway. It inhibits CDK4 and CDK6, proteins involved in cell-cycle progression.

Combining these approaches can provide complementary treatment effects:

  • Endocrine therapy targets hormone-related signaling.
  • Palbociclib targets cell-cycle regulation.
  • The combination can help control cancer growth in patients for whom the regimen is appropriate.

Depending on the treatment setting, palbociclib may be combined with an aromatase inhibitor or fulvestrant. The choice depends on clinical circumstances and the relevant approved indication.

How Is Palbociclib Usually Administered?

A commonly used reference regimen involves taking the prescribed dose once daily for 21 consecutive days, followed by 7 days without palbociclib. This creates a 28-day treatment cycle.

Treatment periodSchedule
Days 1–21Take the prescribed daily dose
Days 22–28Do not take palbociclib
Day 29Start the next cycle if instructed by the oncology team

The schedule may be changed when blood counts or other safety findings require a treatment interruption or dose adjustment.

The food instructions depend on the formulation. Reference palbociclib capsules are taken with food. Reference palbociclib tablets can be taken with or without food. Since the exact Palboxen dosage form has not been confirmed in the supplied information, the package insert must be checked before publishing a product-specific food instruction.

Important Side Effects

Palbociclib may cause adverse reactions that require clinical monitoring.

The most important commonly reported effects include:

  • Neutropenia.
  • Leukopenia.
  • Anemia.
  • Thrombocytopenia.
  • Fatigue.
  • Nausea.
  • Diarrhea.
  • Mouth inflammation.
  • Reduced appetite.
  • Hair thinning.
  • Infections.
  • Abnormal liver-function test results.

Neutropenia is one of the key safety concerns. It involves a reduction in neutrophils, which are white blood cells that help protect the body against bacterial and fungal infections.

Patients should seek prompt medical advice if they develop fever, chills or other possible signs of infection.

Who Should Use Palbociclib?

Palbociclib should only be used by patients whose cancer characteristics and clinical circumstances support treatment with this medicine.

Before prescribing it, the oncology team may review:

  • Breast cancer receptor status.
  • Disease stage and extent.
  • Previous cancer treatments.
  • Menopausal status.
  • Complete blood count.
  • Liver function.
  • Current prescription medicines.
  • Non-prescription medicines and supplements.
  • Pregnancy status where relevant.
  • Other medical conditions.

The medicine should not be used simply because a patient has been diagnosed with breast cancer. A confirmed diagnosis and appropriate treatment assessment are essential.

Precautions Before Starting Treatment

Patients should tell their healthcare professional if they have a history of recurrent infections, liver disease, lung disease or any other significant medical condition.

They should also provide a complete list of medicines and supplements. Some medicines can affect palbociclib levels through the CYP3A enzyme system.

Strong CYP3A inhibitors may increase palbociclib exposure, while strong CYP3A inducers may reduce exposure. These combinations may require avoidance or specialist-directed management.

Patients should not begin a new prescription medicine, herbal preparation or supplement without checking for possible interactions.

Product Identification and Verification

The product name and stated strength alone are not enough to establish the identity or regulatory status of a medicine.

Before using Palboxen, patients and healthcare professionals should check:

  • The complete product name.
  • The active ingredient stated on the packaging.
  • The labeled strength.
  • The dosage form.
  • The manufacturer and manufacturing location.
  • The batch or lot number.
  • The manufacturing and expiry dates.
  • The package integrity.
  • The applicable registration or authorization details.

The supplied information identifies Everest as the company associated with Palboxen. The exact manufacturer, manufacturing facility and regulatory status should be confirmed using the actual product documentation.

Frequently Asked Questions

1. What is Palboxen 125 mg?

Palboxen 125 mg is identified as a palbociclib product. Palbociclib is a targeted CDK4/6 inhibitor used in specified breast cancer treatment combinations.

2. Is Palboxen a chemotherapy medicine?

Palbociclib is classified as targeted anticancer therapy rather than conventional cytotoxic chemotherapy. It still has important adverse effects and requires specialist monitoring.

3. What does palbociclib target?

Palbociclib inhibits CDK4 and CDK6, proteins involved in regulating cell-cycle progression.

4. Why is palbociclib combined with endocrine therapy?

The combination targets two pathways involved in hormone receptor-positive breast cancer: hormone signaling and cell-cycle regulation.

5. Is 125 mg the dose for every patient?

No. Although 125 mg is a commonly used reference starting dose, some patients require a lower dose or treatment interruption.

6. Does palbociclib lower white blood cell counts?

Yes. Neutropenia and leukopenia are important adverse effects, which is why regular blood-count monitoring is necessary.

7. Is Palboxen suitable for HER2-positive breast cancer?

Treatment suitability depends on the specific clinical setting and current local authorization. Patients should not assume that every palbociclib indication applies to every HER2 status.

8. Who decides whether Palboxen is appropriate?

An oncologist or qualified cancer specialist should determine whether palbociclib is appropriate.

Summary

Palboxen 125 mg is presented as a palbociclib-containing product. Palbociclib is a CDK4/6 inhibitor with an established role in selected advanced or metastatic breast cancer treatment regimens, especially HR-positive, HER2-negative disease.

Its use requires an appropriate endocrine treatment partner, regular blood tests, monitoring for adverse effects and professional supervision. Product-specific details should always be confirmed from the actual packaging and applicable official documentation.